Status:
COMPLETED
Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Primary Open Angle Glaucoma
Eligibility:
All Genders
18+ years
Brief Summary
Elevated IOP is a key risk factor for the progression of glaucoma. IOP is subjected to diurnal fluctuation in healthy individuals and higher fluctuation in POAG . So, once-daily antiglaucoma drugs mus...
Eligibility Criteria
Inclusion
- Both genders aged 18 years or more.
- Newly diagnosed POAG cases having :
- IOP more than 21 mmHg Open angle on gonioscopy Showing both structural and functional damage (confirmed with OCT and visual field)
Exclusion
- Angle closure glaucoma.
- Secondary glaucomas.
- Advanced glaucoma likely to be uncontrolled on monotherapy or needing a low target IOP.
- History of ocular trauma, laser or intraocular surgery.
- Any other ocular disorder including uveitis and cystoid macular edema.
- Known history of allergy or sensitivity to any components of the study medications.
Key Trial Info
Start Date :
June 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04461249
Start Date
June 1 2019
End Date
April 1 2020
Last Update
July 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr El-Aini hospital
Cairo, Egypt